The final data, containing epidemiological, clinical manifestation, laboratory indicators, radiological features, treatment and outcomes, were obtained from the electronic medical records. After admission, nucleic acid test and high-resolution CT pulmonary scanning were performed immediately. We collected clinical manifestations data of all suspected patients, including fever, fatigue, dry cough, expectoration, running nose, pharyngalgia, headache, and some gastrointestinal symptoms such as abdominal discomfort, abdominal pain, nausea, vomiting, diarrhea. Laboratory examinations were obtained, including blood routine, blood clotting index, hepatorenal function, myocardial enzyme, procalcitonin (PCT), C reactive protein (CRP), erythrocyte sedimentation rate (ESR), and other pathogens as influenza B, mycoplasma pneumoniae, chlamydia pneumoniae. Typical CT findings were defined as interstitial changes and multiple small plaques in the lung periphery at early-stage, with further deteriorated to bilateral multiple ground-glass opacities or infiltrating shadows. Lung consolidation was observed in severe cases; pleural effusion was rare. The normal range of white blood cell (WBC) counts was 5 - 10 × 10
9/L while lymphocyte counts were 1.1 - 3.2 × 10
9/L. Suspected cases were defined as those who had an epidemiological history and two of the following clinical manifestations: (a) Fever, fatigue, dry cough; (b) chest CT findings as mentioned above; (c) in the early stage, WBC count was normal or decreased, or lymphocyte count decreased; (d) no other pathogens were detected to explain the clinical manifestations. Confirmed cases were defined as suspected cases with 2019-nCoV nucleic acid positive. The release and discharge criteria included: (a) normal body temperature for more than three days in a row; (b) obvious improvement of the respiratory symptoms; (c) negative nCoV-RNA finding in two consecutive tests with an interval of at least one day (
9).